

03rd February, 2017

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

✓ The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,


Sub.: Presentation to analysts on un-audited Financial Results for the quarter and nine months ended 31st December, 2016

The presentation on un-audited Financial Results for the quarter and nine months ended 31st December, 2016 made to analysts is enclosed for your record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL

VP (LEGAL) & COMPANY SECRETARY

Encl.: As above



Q3 & YTD Dec 2016-17



Consolidated Revenues for Q3 2016-17

(` Crore)

Particulars	Q3 1617	Q3 1516	Gr%
India	503	448	12%
US	310	558	-44%
Brazil	159	118	35%
Germany	204	164	24%
Other	120	108	11%
Others (Incl contract Mfg.)	147	146	1%
Total	1,443	1,542	-6%



Consolidated Revenues for YTD Dec 2016-17

(` Crore)

Particulars	YTD Dec 1617	YTD Dec 1516	Gr%
India	1,509	1,383	9%
US	1,065	2,158	-51%
Brazil	484	387	25%
Germany	577	485	19%
Other	361	323	12%
Others (Incl contract Mfg.)	427	449	-5%
Total	4,423	5,184	-15%

